For example, in gastric cancer patients with high expression of CLDN18.2, only 12% express HER2, indicating that only 12% of gastric cancer patients may have a good response to HER2 and CLDN18.2 dual target CAR-T therapy. The gene discussed is ERBB2; the disease is gastric cancer.